CIBC World Markets’s Dr. Reddy's Laboratories RDY Stock Holding History

CIBC World Markets’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-125,000	Closed	-$1.64M	–	657
2021 Q4	$1.64M	Buy	+125,000	New	+$1.58M	0.01%	418

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC World Markets's RDY Position: Q1 2022 in Review

CIBC World Markets sold out of Dr. Reddy's Laboratories (RDY) in Q1 2022, closing a stake of 125,000 shares — an estimated $1.64M sold.

CIBC World Markets first reported a position in RDY in Q4 2021 and held it in 1 quarter. The position peaked at $1.64M in Q4 2021. 146 funds tracked by Wall St. Rank hold RDY as of Q1 2022.

CIBC World Markets reported no remaining Dr. Reddy's Laboratories position as of Q1 2022 after selling out during the quarter.
CIBC World Markets sold 125,000 Dr. Reddy's Laboratories shares in Q1 2022, an estimated $1.64M.
CIBC World Markets first reported a position in Dr. Reddy's Laboratories in Q4 2021 and held it in 1 quarter.
CIBC World Markets's Dr. Reddy's Laboratories position peaked at $1.64M in Q4 2021.
146 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2022.

Based on CIBC World Markets's 13F filing for Q1 2022, filed 13 May 2022.